Transcend Capital Advisors LLC Sells 1,799 Shares of Cencora, Inc. (NYSE:COR)

Transcend Capital Advisors LLC trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 11.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,470 shares of the company’s stock after selling 1,799 shares during the period. Transcend Capital Advisors LLC’s holdings in Cencora were worth $3,251,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of COR. Suncoast Equity Management raised its position in shares of Cencora by 2.2% during the fourth quarter. Suncoast Equity Management now owns 27,407 shares of the company’s stock worth $6,158,000 after purchasing an additional 591 shares during the period. Nicholson Wealth Management Group LLC raised its position in shares of Cencora by 6.3% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 7,922 shares of the company’s stock worth $1,780,000 after purchasing an additional 466 shares during the period. Dash Acquisitions Inc. acquired a new position in shares of Cencora during the fourth quarter worth approximately $176,000. Concurrent Investment Advisors LLC raised its position in shares of Cencora by 4.5% during the fourth quarter. Concurrent Investment Advisors LLC now owns 8,046 shares of the company’s stock worth $1,808,000 after purchasing an additional 349 shares during the period. Finally, Bryn Mawr Capital Management LLC raised its position in shares of Cencora by 335.4% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 25,863 shares of the company’s stock worth $5,811,000 after purchasing an additional 19,923 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 0.8 %

Shares of Cencora stock opened at $243.42 on Friday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26. The firm has a market cap of $47.20 billion, a PE ratio of 34.63, a P/E/G ratio of 1.29 and a beta of 0.49. The stock has a fifty day moving average price of $239.34 and a 200-day moving average price of $237.46. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.